Updates in Drug Treatment of Severe Hypertriglyceridemia.
ARO-ANG3
ARO-APOC3
Hypertriglyceridemia-induced acute pancreatitis
Olezarsen
Triglycerides
Volanesorsen
Journal
Current atherosclerosis reports
ISSN: 1534-6242
Titre abrégé: Curr Atheroscler Rep
Pays: United States
ID NLM: 100897685
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
accepted:
15
08
2023
medline:
11
10
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
To provide an insight into the new pharmacological options for the treatment of severe hypertriglyceridemia (sHTG). sHTG is difficult to treat. The majority of the traditional pharmacological agents available have limited success in both robustly decreasing triglyceride levels and/or in reducing the incidence of acute pancreatitis (AP), the most severe complication of sHTG. Therapeutic options with novel mechanisms of action have been developed, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA) targeting APOC3 and ANGPTL3. The review discusses also 2 abandoned drugs for sHTG treatment, evinacumab and vupanorsen. The ASO targeting APOC3, volanesorsen, is approved for use in patients with familial chylomicronemia syndrome (FCS) in Europe. Olezarsen, an N-acetylgalactosamine (GalNAc)-conjugated ASO with the same target, seems to have a better safety and efficacy profile. siRNA targeting APOC3 and ANGPTL3, namely ARO-APOC3 and ARO-ANG3, are also promising for the treatment of sHTG. However, the ultimate clinical goal of any sHTG treatment, the decrease in the risk of AP, has not been definitively achieved till now by any pharmacotherapy, either approved or in development.
Identifiants
pubmed: 37642858
doi: 10.1007/s11883-023-01140-z
pii: 10.1007/s11883-023-01140-z
pmc: PMC10564803
doi:
Substances chimiques
vupanorsen
0
Triglycerides
0
Oligonucleotides, Antisense
0
Apolipoprotein C-III
0
RNA, Small Interfering
0
ANGPTL3 protein, human
0
Angiopoietin-Like Protein 3
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
701-709Informations de copyright
© 2023. The Author(s).
Références
Atherosclerosis. 2016 Mar;246:229-35
pubmed: 26803432
J Clin Lipidol. 2023 May-Jun;17(3):342-355
pubmed: 37100699
N Engl J Med. 2017 Jul 20;377(3):211-221
pubmed: 28538136
Am J Hum Genet. 2014 Feb 6;94(2):223-32
pubmed: 24507774
Diabetes Care. 2016 Aug;39(8):1408-15
pubmed: 27271183
J Clin Lipidol. 2012 Sep-Oct;6(5):450-61
pubmed: 23009781
Lancet Diabetes Endocrinol. 2021 May;9(5):264-275
pubmed: 33798466
Front Cardiovasc Med. 2022 Apr 14;9:886266
pubmed: 35498015
Curr Opin Lipidol. 2021 Aug 1;32(4):271-272
pubmed: 34227579
N Engl J Med. 2014 Jul 3;371(1):22-31
pubmed: 24941081
Expert Opin Pharmacother. 2023 Jun;24(9):1013-1020
pubmed: 37114828
N Engl J Med. 2019 Aug 8;381(6):531-542
pubmed: 31390500
N Engl J Med. 2017 Jul 20;377(3):222-232
pubmed: 28538111
Circulation. 2022 May 3;145(18):1377-1386
pubmed: 35369705
Curr Opin Lipidol. 2020 Dec;31(6):331-339
pubmed: 33027225
Expert Rev Cardiovasc Ther. 2021 Aug;19(8):685-693
pubmed: 34261380
Expert Rev Clin Pharmacol. 2022 Apr;15(4):395-405
pubmed: 35762447
Eur Heart J. 2022 Apr 6;43(14):1401-1412
pubmed: 35025993
Circulation. 2019 Jun 18;139(25):e1082-e1143
pubmed: 30586774
Nat Med. 2023 Mar;29(3):729-737
pubmed: 36879129
Atherosclerosis. 2023 Jun;375:67-74
pubmed: 37253281
J Clin Endocrinol Metab. 2012 Jul;97(7):E1266-75
pubmed: 22659251
Curr Opin Lipidol. 2022 Apr 1;33(2):133-138
pubmed: 34907967
J Clin Lipidol. 2022 Sep-Oct;16(5):617-625
pubmed: 35902351
J Clin Lipidol. 2022 Nov-Dec;16(6):833-849
pubmed: 36402670
J Lipid Res. 2020 Aug;61(8):1203-1220
pubmed: 32487544
Eur Heart J. 2022 Apr 6;43(14):1413-1415
pubmed: 35174387
Eur Heart J. 2020 Oct 21;41(40):3936-3945
pubmed: 32860031
Am J Cardiol. 2000 May 1;85(9):1100-5
pubmed: 10781759
N Engl J Med. 2014 Jul 3;371(1):32-41
pubmed: 24941082
J Clin Lipidol. 2023 May-Jun;17(3):406-411
pubmed: 37164837
N Engl J Med. 2019 Jan 3;380(1):11-22
pubmed: 30415628
Lipids Health Dis. 2021 May 25;20(1):55
pubmed: 34034750